Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 5, 2000, Pages 639-650

  Somasundaram, S ^a   Sigthorsson, G ^a   Simpson, R J ^a   Watts, J ^a   Jacob, M ^a   Tavares, I A ^a   Rafi, S ^a   Roseth, A ^a   Foster, R ^a   Price, A B ^a,b   Wrigglesworth, J M ^a,c   Bjarnason, I ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Northwick Pk and St Mark's H ^*  (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DINITROPHENOL; ACETYLSALICYLIC ACID; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROSTANOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENTERITIS; ENTEROPATHY; ENZYME INHIBITION; INTESTINE MUCOSA PERMEABILITY; MALE; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PATHOGENESIS; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DUODENUM; ENTEROCYTES; INTESTINAL ABSORPTION; INTESTINAL DISEASES; INTESTINAL MUCOSA; MALE; MITOCHONDRIA; OXIDATIVE PHOSPHORYLATION; OXIDATIVE PHOSPHORYLATION COUPLING FACTORS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; RATS; RATS, SPRAGUE-DAWLEY; UNCOUPLING AGENTS;

EID: 0034097624     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00723.x     Document Type: Article

References (70)

1. 1 Barrier CH, Hirschowtz BI. Current controversies in rheumatology. Controversies and management of non-steroidal anti-inflammatory drug induced side effects on upper gastrointestinal tract. Arthritis Rheum 1989; 32: 926-9.
2. 2 Bjarnason I. Hayllar J, Macpherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine. Gastroenterology 1993; 104: 1832-47.
3. 3 Wallace JL. Non-steroidal anti-inflammatory drug gastropathy and cytoprotection: Pathogenesis and mechanisms re-examined. Scand J Gastroenterol 1992: 27(Suppl 192): 3-8.
4. 4 Somasundaram S, Hayllar J, Rafi S, Wrigglesworth J. Macpherson A, Bjarnason I. The biochemical basis of NSAID-induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol 1995; 30: 289-99.
5. 5 Whittle BJR. Unwanted effects of aspirin and related agents on the gastrointestinal tract. In: Vane JR, Botting RM, eds. Aspirin and Other Salicylates. London: Chapman & Hall Medical, 1992: 465-509.
6. 6 Levine RA, Petokas S, Nandi J. Enthoven D. Effects of nonsteroidal anti-inflammatory drugs on gastrointestinal injury and prostanoid generation in healthy volunteers. Dig Dis Sci 1988; 33: 660-6.
7. 7 Ligumski M, Golanska EM, Hansen DG, Kauffman GL. Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in the rat. Gastroenterology 1983; 84: 756-61.
8. 8 Ivey KJ, Poane DB, Krause WJ. Acute effect of systemic aspirin on gastric mucosa in man. Dig Dis Sci 1980; 25: 97-9.
9. 9 Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduced arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995; 83: 483-92.
10. 10 Whittle BJR. Protective mechanisms of the gastric mucosa. In: Gustsavsson S, Kumar D, Graham DY, eds. The Stomach. Edinburgh: Churchill Livingstone, 1992: 81-101.
11. 11 Whittle BJR. Mechanism underlying gastric mucosal damage induced by indomethacin and bile salt, and the actions of prostaglandins. Br J Pharmacol 1977; 60: 455-60.
12. 12 Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112: 1000-16.
13. 13 Lichtenberger LM, Wang Z-M. Romero JJ, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: Insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nature Med 1995; 1: 154-8.
14. 14 Lichtenberger LM, Romero JJ, Wang ZM. ASA forms an ionic complex with phosphatidylcholine: Possible molecular explanation for its ulcerogenic action. Gastroenterology 1994; 106: A134(Abstract).
15. 15 Whitehouse MW. Biochemical properties of anti-inflammatory drugs-III. Uncoupling of oxidative phosphorylation in a connective tissue (cartilage) and liver mitochondria by salicylate analogues: relationship of structure to activity. Biochem Pharmacol 1964; 13: 319-36.
16. 16 Mahmud T. Rafi SS, Scott DL, Wrigglesworth JM, Bjarnason I. Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. Arth Rheum 1996; 59: 1998-2003.
17. 17 Anthony A, Gahl AK, Dhillon AP, et al. The beta 3-adrenoreceptor agonist CL3162343 prevents indomethacin-induced jejunal ulceration in the rat by reversing early villous shortening. J Pathol 1996; 179: 340-6.
18. 18 Kelly D. Piasecki C, Anthony A, Pounder RE, Wakefield AJ. Early indomethacin lesions in rat jejunum: reduced focal blood flow and shortening of villi precede ulceration. Gut 1998; 42: 366-73.
19. 19 Anthony A, Pounder RE, Dhillon AP, Wakefleld AJ. Vascular anatomy defines sites of indomethacin induced jejunal ulceration along the mesenteric margin. Gut 1997; 41: 763-70.
20. 20 Tokumitsu Y, Lee S, Ut M. In vitro effects of nonsteroidal anti-inflammatory drugs on oxidative phosphorylation in rat liver mitochondria. Biochem Pharmacol 1977; 26: 2101-6.
21. 21 Vane JR, Botting RM. Overview-mechanisms of action of antiinflammatory drugs. In: Improved Non-Steroidal Anti-Inflammatory Drugs. COX-2 Enzyme Inhibitors. Vane J, Botting J, Botting R, eds. Dordrecht: Kluwer Academic Publishers, 1996: 1-27.
22. 22 Vane JR. Towards a better aspirin. Nature 1994; 367: 215-6.
23. 23 Somasundaram S, Rafi S, Hayllar J, et al. Mitochondrial damage: a possible mechanism of the 'topical' phase of NSAID-induced injury to the rat intestine. Gut 1997; 41: 344-53.
24. 24 Brodie DA, Tatae CL, Hooke KF. Aspirin. Intestinal damage in rats. Science 1970; 170: 183-5.
25. 25 Mahmud T, Somasundaram S, Sigthorsson G, et al. Enantiomers of flurbiprofen can distingush key pathophysiological steps of NSAID-enteropathy in the rat by steroselective inhibition of cyclooxygenase. Gut 1998; 43: 775-82.
26. 26 Somasundaram S, Rafi S, Jacob M, et al. Intestinal tolerability of nitroxybutyl-flurbiprofen in rats. Gut 1997; 40: 608-13.
27. 27 Sigthorsson G, Jacob M, Wrigglesworth JM, et al. A comparison of indomethacin and nimesulide, a selective cyclooxygenase-2 inhibitor, on key pathophysiological steps in the pathogenesis of NSAID enteropathy in the rat. Scand J Gastroenterol 1998; 33: 728-35.
28. 28 Schneider WC, Hogeboom GH. Intracellular distribution of enzymes V. Further studies on the distribution of cytochrome c in rat liver homogenates. J Biol Chem 1950; 183: 123-8.
29. 29 McLaughlin SGA, Dilger JP. Transport of protons across membranes by weak acids. Physiol Rev 1980; 60: 825-63.
30. 30 Chance B, Williams GR. The respiratory chain and oxidative phosphorylation. Adv Enzymol 1956; 17: 65-134.
31. 31 Tavares IA, Bennett A. Acemetacin and indomethacin: Differential inhibition of constitutive and inducible cyclo-oxygenase in human gastric mucosa and leukocytes. Int J Tiss Reac 1993; 15: 49-53.
32. 32 Tavares IA, Collins PO, Bennett A. Inhibition of prostanoid synthesis by human gastric mucosa. Aliment Pharmacol Ther 1987; 1: 617-26.
33. 33 Meddings JB, Gibbons I. Discrimination of site-specific alterations in gastrointestinal permeability in the rat. Gastroenterology 1998; 114: 83-92.
34. 34 Davies NM, Corrigan BW, Jamali F. Sucrose urinary excretion in the rat measured using a simple assay: a model for gastroduodenal permeability. Pharm Res 1995; 12: 1733-6.
35. 35 Maxton DG, Catt SD, Menzies IS. Intestinal disaccharidases assessed in congenital asucrasia by differential urinary disaccharide excretion. Dig Dis Sci 1989; 34: 129-31.
36. 36 Ford J, Martin SW, Houston JB. Assessment of intestinal permeability changes induced by non-steroidal anti-inflammatory drugs in the rat. J Pharmacol Toxicol Meth 1995; 35: 9-16.
37. 37 Ford J, Houston JB. Concentration-response relationships for three non-steroidal anti-inflammatory drugs in the rat intestine. Hum Exp Toxicol 1995; 14: 573-9.
38. 38 Davies NM, Wright MR, Jamali F. Anti-inflammatory drug induced small intestinal permeability: The rat is a suitable model. Pharmac Res 1994; 11: 1652-6.
39. 39 Bjarnason I, Smethurst P, Levi AJ, Peters TJ. Intestinal permeability to 51CrEDTA in rats with experimentally induced enteropathy. Gut 1985; 26: 579-85.
40. 40 Reuter BK, Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug enteropathy in rats: Role of permeability, bacteria, and enterohepatic circulation. Gastroentcrology 1997; 112: 109-17.
41. 41 Roseth AG, Foster R, Fagerhol MK, Peters TJ. Somasundaram S, Bjarnason I. Isolation, purification and assessment of a novel faecal granulocyte marker protein (GMP) in rats: temporal relationship between intestinal permeability and inflammation in NSAID enteropathy. Scand J Clin Invest 2000: in press.
42. 42 Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating calprotectin in feces. A meathodologic study. Scand J Gastroenterol 1992; 27: 793-8.
43. 43 Davies NM, Roseth AG, Appleyard CB. et al. NO-naproxen versus naproxen: Ulcerogenic, analgesic and anti-inflammatory effect. Aliment Pharmacol Ther 1997; 11: 69-79.
44. 44 Moreland DE. Effects of toxicants on oxidative phosphorylation and photophosphorylation. In: Hodgson G, Levi PE, eds. Introduction to Biochemical Toxicology. Norwalk: Appleton and Lange, 1994: 345-66.
45. 45 Tyler DD. Respiratory enzyme systems of mitochondria. In: The Mitochondria in Health and Disease. New York: VCH Publishers, 1991.
46. 46 Kargman S, Charleson S, Cartwright M, et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1996; 111: 445-54.
47. 47 Rafi S. Studies on the pathogenesis of NSAID enteropathy, with special reference to mitochondria. PhD Thesis, University of London, 1999.
48. 48 Spenny JG, Bhown M. Effect of prostaglandin acid on gastric mucosa II. Mucosal ATP and phosphocreatinine content and salicylic effects on mitochondrial metabolism. Gastroenterology 1977; 73: 995-9.
49. 49 Carefoli E. Intra cellular calcium homeostasis. Ann Rev Biochem 1987; 56: 395-433.
50. 50 Kretsinger RH. Evolution and function of calcium binding proteins. Int Rev Cyt 1976; 46: 323-93.
51. 2+, and cytotoxicity in the rat hepatocytes. J Biol Chem 1992; 267: 6654-63.
52. 2+. Biochem Biophys Acta 1980; 592: 396-405.
53. 53 Madara JL, Barenberg D, Carlson S. Effect of cytochalasin D on occluding junctions of intestinal absorptive cells: further evidence that the cytoskeleton may influence paracellular permeability and junctional charge selectivity. J Cell Biol 1986; 102: 2125-36.
54. 54 Wright MR, Davies NM, Jamali F. Toxicokinetics of indomethacin-induced intestinal permeability in the rat. Pharmacol Res 1997; 35: 499-504.
55. 55 Davies NM, Jamali F. Influence of flubiprofen dosage form of gastroenteropathy in the rat: Evidence of shift in the toxicity site. Pharm Res 1997; 11: 255-9.
56. 56 Mahmud T, Scott D, Bjarnason I. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Ann Rheum Dis 1996; 55: 211-3.
57. 2 synthase-1. Nature 1994; 367: 243-9.
58. 58 Garavito RM. The three-dimensional structure of cyclooxygenases. Improved Non-steroidal Anti-inflammatory Drugs. CoX-2 Enzyme Inhibitors. In: Vane J, Botting J, Botting R, eds. Dordreicht: Kluwer Academic Publishers, 1996: 29-43.
59. 59 Herbette LG, Vecchiarelli M, Trummlitz G. NSAID mechanism of action: the role of intracellular pharmacokinetics. Improved Non-steroidal Anti-inflammatory Drugs. CoX-2 Enzyme Inhibitors. In: Vane J, Botting J, Botting R, eds. Dordreicht: Kluwer Academic Publishers, 1996: 85-102.
60. 60 Lokken P. Studies on 51CrEDTA and its evaluation as a reference substance in gastrointestinal disease. Norwegian Monographs in Medical Science. Oslo: Universforlaget, 1970.
61. 61 Meddings JB, Sutherland LR, Byles NI, Wallace JL. Sucrose: a novel permeability marker for gastroduodenal disease. Gastroenterology 1993; 105: 1619-26.
62. 62 Insel PA. Analgesic-antipyretics and anti-inflammatory agents: Drugs employed in the treatment of rheumatoid arthritis and gout. In: Gillman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, Eight Edition. New York: McGraw-Hill, 1993: 638-81.
63. 63 Bugat R, Thompson MR, Aures D, Grossman MI. Gastric mucosal lesions produced by intravenous infusion of aspirin in cats. Gastroenterology 1976; 71: 754-9.
64. 64 Vey K, Paone DB, Krause WR. Acute effect of systemic aspirin on gastric mucosa in man. Dig Dis Sci 1980; 25: 549-52.
65. 65 Gardner A, Allen A. Gastroduodenal mucosal defence mechanisms and the action of non-steroidal anti-inflammatory agents. Scand J Gastroenterol 1987: 22(Suppl. 127): 29-34.
66. 66 Wallace JL, Keenan CM, Granger DN. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil dependent process. Am J Physiol 1990; 259: G462-G567.
67. 67 Wallace JL, Granger DN. Pathogenesis of NSAID gastropathy: are neutrophils the culprits? Trends Pharmacol Sci 1992; 13: 129-30.
68. 68 Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in rat. Gastroenterology 1994; 107: 173-9.
69. 69 Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino GA. A didofenac derivative without ulcerogcnic properties. Eur J Pharmacol 1994; 257: 249-55.
70. 70 Anthony A, Trasivoulou C, Dhillon AP, Pounder RE, Wakefield AJ. Pre-ulcerative villous contraction and microvascular occlusion induced by indomethacin in the rat jejunum. Aliment Pharmacol Ther 1995; 9: 605-13.